Ewopharma and Biogen have signed a distribution agreement to market and sell Biogen’s anti-Tumor Necrosis Factor (anti-TNF) biosimilars.
This year, Ewopharma will bring BENEPALI® (etancercept) and FLIXABI® (infliximab) to six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania. BENEPALI and FLIXABI are indicated to treat a number of inflammatory diseases, including rheumatoid arthritis, psoriasis, ankylosing spondylitis and inflammatory bowel disease.
BENEPALI® and FLIXABI®, among the first biosimilar anti-TNF therapies in Central Eastern Europe, both inhibit the actions of Tumor Necrosis Factor-alpha (TNF-alpha), a key player of the immune system. TNF-alpha’s primary role is the regulation of immune cells in in the defence against viral infection, inhibition of tumorigenesis or response to sepsis to name but a few. If TNF-alpha is unregulated, however, this can lead to unwanted systemic inflammation, which causes the symptoms of rheumatoid arthritis or psoriasis for example. Inhibiting TNF-alpha’s pathological effects will threfore provide relief to sufferers of TNF-alpha-related autoimmune disorders such as rheumatoid arthritis.
Alain Staub, CEO and Chairman of the Board of Ewopharma, said: “Ewopharma has a long-standing history of bringing new medicines to patients in Central Eastern Europe. We are therefore very pleased to partner with Biogen to bring their anti-TNF therapies to patients, physicians, and payers.”